Show simple item record

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

dc.contributor.authorSeckl, M.en
dc.contributor.authorGhorani, E.en
dc.contributor.authorQuartagno, M.en
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorGilbert, D. C.en
dc.contributor.authorO'Brien, M. E. R.en
dc.contributor.authorOttensmeier, C. H. H.en
dc.contributor.authorPizzo, E.en
dc.contributor.authorSpicer, J. F.en
dc.contributor.authorWilliams, A.en
dc.contributor.authorBadman, P. D.en
dc.contributor.authorParmar, M. K. B.en
dc.date.accessioned2023-10-25T08:48:39Z
dc.date.available2023-10-25T08:48:39Z
dc.date.issued2023en
dc.identifier.citationSeckl M, Ghorani E, Quartagno M, Blackhall FH, Gilbert DC, O'Brien MER, et al. REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005494.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS9145en
dc.identifier.urihttp://hdl.handle.net/10541/626665
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9145en
dc.titleREFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm designen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentImperial College London, Londonen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record